Review



pe anti human cd80  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems pe anti human cd80
    Comparison of the phenotypic profiles of DCLCs primed with or without IFIT4 over-expression. (a) Surface antigens of normal THP-1 cells were examined by flow cytometry. (b) To analyze the effect of IFIT4 on phenotypic changes of dendritic cell-like cells (DCLCs) during the process of differentiation, THP-1 cells were transfected with pEGFP-IFIT4 or pEGFP-C1; 36 hours later, cells were stimulated with granulocyte-macrophage colony-stimulating factor (GM-CSF; 50 ng/ml) and IL-4 (20 ng/ml) for 90 hours to generate DCLCs. These DCLCs primed with pEGFP-IFIT4 or pEGFP-C1 transfection were incubated with fluorochrome-conjugated monoclonal antibodies (mAbs) and the antigens of CD40, <t>CD80,</t> CD86, CD83, HLA-DR, CD14 and CD1a on the surface of those DCLCs were analyzed by flow cytometry. Appropriate fluorochrome or isotype control mAbs of each antibody species were used as negative controls. Shaded histograms represent isotype control antibodies. The thick line represents DCLCs primed with pEGFP-IFIT4 transfection, whereas the slender lines represent DCLCs primed with pEGFP-C1 transfection. All experiments were performed three times and a set of representative histograms was presented. IFIT4, interferon-induced protein with tetratricopeptide repeats 4.
    Pe Anti Human Cd80, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd80/Human+B7-1%2FCD80+PE-conjugated+Antibody/pmc02575605-82-7-15
    Average 94 stars, based on 10 article reviews
    pe anti human cd80 - by Bioz Stars, 2026-11
    94/100 stars

    Images

    1) Product Images from "Interferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cells"

    Article Title: Interferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cells

    Journal: Arthritis Research & Therapy

    doi: 10.1186/ar2475

    Comparison of the phenotypic profiles of DCLCs primed with or without IFIT4 over-expression. (a) Surface antigens of normal THP-1 cells were examined by flow cytometry. (b) To analyze the effect of IFIT4 on phenotypic changes of dendritic cell-like cells (DCLCs) during the process of differentiation, THP-1 cells were transfected with pEGFP-IFIT4 or pEGFP-C1; 36 hours later, cells were stimulated with granulocyte-macrophage colony-stimulating factor (GM-CSF; 50 ng/ml) and IL-4 (20 ng/ml) for 90 hours to generate DCLCs. These DCLCs primed with pEGFP-IFIT4 or pEGFP-C1 transfection were incubated with fluorochrome-conjugated monoclonal antibodies (mAbs) and the antigens of CD40, CD80, CD86, CD83, HLA-DR, CD14 and CD1a on the surface of those DCLCs were analyzed by flow cytometry. Appropriate fluorochrome or isotype control mAbs of each antibody species were used as negative controls. Shaded histograms represent isotype control antibodies. The thick line represents DCLCs primed with pEGFP-IFIT4 transfection, whereas the slender lines represent DCLCs primed with pEGFP-C1 transfection. All experiments were performed three times and a set of representative histograms was presented. IFIT4, interferon-induced protein with tetratricopeptide repeats 4.
    Figure Legend Snippet: Comparison of the phenotypic profiles of DCLCs primed with or without IFIT4 over-expression. (a) Surface antigens of normal THP-1 cells were examined by flow cytometry. (b) To analyze the effect of IFIT4 on phenotypic changes of dendritic cell-like cells (DCLCs) during the process of differentiation, THP-1 cells were transfected with pEGFP-IFIT4 or pEGFP-C1; 36 hours later, cells were stimulated with granulocyte-macrophage colony-stimulating factor (GM-CSF; 50 ng/ml) and IL-4 (20 ng/ml) for 90 hours to generate DCLCs. These DCLCs primed with pEGFP-IFIT4 or pEGFP-C1 transfection were incubated with fluorochrome-conjugated monoclonal antibodies (mAbs) and the antigens of CD40, CD80, CD86, CD83, HLA-DR, CD14 and CD1a on the surface of those DCLCs were analyzed by flow cytometry. Appropriate fluorochrome or isotype control mAbs of each antibody species were used as negative controls. Shaded histograms represent isotype control antibodies. The thick line represents DCLCs primed with pEGFP-IFIT4 transfection, whereas the slender lines represent DCLCs primed with pEGFP-C1 transfection. All experiments were performed three times and a set of representative histograms was presented. IFIT4, interferon-induced protein with tetratricopeptide repeats 4.

    Techniques Used: Comparison, Over Expression, Flow Cytometry, Transfection, Incubation, Bioprocessing, Control

    Related Articles

    Staining:

    Article Title: Sulforaphane Epigenetically Regulates Innate Immune Responses of Porcine Monocyte-Derived Dendritic Cells Induced with Lipopolysaccharide
    Article Snippet: .. Cells were stained with a mouse anti-human CD40 FITC Ab (clone G28.5, NB100-77786, Novus Biologicals), a mouse anti-human CD80 PE Ab (clone 37711, FAB140P, R&D systems) and a mouse anti-human CD86 APC Ab (clone 37301, FAB141A, R&D systems) antibodies. ..

    Article Title: A Therapeutic Vaccine in Combination with Cyclic GMP-AMP Cures More Differentiated Melanomas in Mice.
    Article Snippet: RESEARCH ARTICLE | MARCH 22 2023 A Therapeutic Vaccine in Combination with Cyclic GMP–AMP Cures More Di erentiated Melanomas in Mice Md Masud Alam; ... et. al J Immunol (2023) 210 (9): 1428–1436. https://doi.org/10.4049/jimmunol.2200371 Related Content Therapeutic Vaccine (TheraVac) in combination with cGAMP cures more differentiated melanomas in mice J Immunol (May,2021) Development of a curative therapeutic vaccine (TheraVac) for the treatment of large established tumors J Immunol (May,2017) Development of a Curative Immunotherapeutic Strategy for the Treatment of Big Established CT26 Tumors J Immunol (May,2016) D ow nloaded from http://journals.aai.org/jim m unol/article-pdf/210/9/1428/1645175/ji2200371.pdf by guest on 05 April 2024

    Flow Cytometry:

    Article Title: A Therapeutic Vaccine in Combination with Cyclic GMP-AMP Cures More Differentiated Melanomas in Mice.
    Article Snippet: RESEARCH ARTICLE | MARCH 22 2023 A Therapeutic Vaccine in Combination with Cyclic GMP–AMP Cures More Di erentiated Melanomas in Mice Md Masud Alam; ... et. al J Immunol (2023) 210 (9): 1428–1436. https://doi.org/10.4049/jimmunol.2200371 Related Content Therapeutic Vaccine (TheraVac) in combination with cGAMP cures more differentiated melanomas in mice J Immunol (May,2021) Development of a curative therapeutic vaccine (TheraVac) for the treatment of large established tumors J Immunol (May,2017) Development of a Curative Immunotherapeutic Strategy for the Treatment of Big Established CT26 Tumors J Immunol (May,2016) D ow nloaded from http://journals.aai.org/jim m unol/article-pdf/210/9/1428/1645175/ji2200371.pdf by guest on 05 April 2024

    Blocking Assay:

    Article Title: A Therapeutic Vaccine in Combination with Cyclic GMP-AMP Cures More Differentiated Melanomas in Mice.
    Article Snippet: RESEARCH ARTICLE | MARCH 22 2023 A Therapeutic Vaccine in Combination with Cyclic GMP–AMP Cures More Di erentiated Melanomas in Mice Md Masud Alam; ... et. al J Immunol (2023) 210 (9): 1428–1436. https://doi.org/10.4049/jimmunol.2200371 Related Content Therapeutic Vaccine (TheraVac) in combination with cGAMP cures more differentiated melanomas in mice J Immunol (May,2021) Development of a curative therapeutic vaccine (TheraVac) for the treatment of large established tumors J Immunol (May,2017) Development of a Curative Immunotherapeutic Strategy for the Treatment of Big Established CT26 Tumors J Immunol (May,2016) D ow nloaded from http://journals.aai.org/jim m unol/article-pdf/210/9/1428/1645175/ji2200371.pdf by guest on 05 April 2024



    Similar Products

    94
    Miltenyi Biotec cd80
    Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
    Cd80, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd80/CD80+Antibody%2C+anti-mouse%2C+REAfinity/pmc13694607-279-21-25
    Average 94 stars, based on 1 article reviews
    cd80 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    InvivoGen jurkat cells
    Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
    Jurkat Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd80/CTLA-4%2FCD80+Bio-IC/pm42546824-117-15-18
    Average 94 stars, based on 1 article reviews
    jurkat cells - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology cd80 fitc
    Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
    Cd80 Fitc, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd80/FITC+Anti-Mouse+CD80+Antibody/pm42909153-502-24-26
    Average 94 stars, based on 1 article reviews
    cd80 fitc - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology bv 2 activation
    Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
    Bv 2 Activation, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd80/CD80+Rabbit+pAb/10__20517_slash_evcna__2026__91-105-2-17
    Average 94 stars, based on 1 article reviews
    bv 2 activation - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Novus Biologicals cd80
    Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
    Cd80, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd80/B7-1%2FCD80+Antibody+(2D10%2E4)+%5BAllophycocyanin%2FCy7%5D/pm42834086-288-31-33
    Average 94 stars, based on 1 article reviews
    cd80 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology anti cd80
    Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
    Anti Cd80, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd80/FITC+Anti-Mouse+CD80+Antibody/pm42829139-144-17-18
    Average 94 stars, based on 1 article reviews
    anti cd80 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology pe anti mouse cd80
    Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
    Pe Anti Mouse Cd80, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd80/PE+Anti-Mouse+CD80+Antibody/10__1038_slash_s41467___026___77873___7-389-7-53
    Average 94 stars, based on 1 article reviews
    pe anti mouse cd80 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    96
    Proteintech cd80
    Time-dependent differentiation and phenotypic maturation of human monocytes into macrophages. (A) Schematic of the experimental timeline. Upper panel: culture conditions; lower panel: analyses at each time point. Analyses on days 6 and 7 were conducted prior to polarization. (B) Classification of monocyte subsets (CD14/CD16) and macrophages phenotypes (CD68/CD86/CD163). (C) Flow cytometric analysis of monocyte subsets at days 0, 4, 6, and 7 without polarization or neutrophils. Dot plots show CD14/CD16, CD14 + CD86/CD163, CD86/CD163, and CD14/CD68. (D) Representative immunofluorescence images on days 4 and 7 (pre-polarization) under IFN-γ/LPS and IL-4/IL-13 conditions; DAPI (blue), CD68 (green), <t>CD80</t> or CD206 (red). Scale bars, 100 µm. (E) Quantification of CD68 + CD86 + and CD68 + CD163 + macrophages under IFN-γ/LPS and IL-4/IL-13 conditions on day 7 (pre-polarization). n = 5 independent donors.
    Cd80, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd80/CD80%2FB7-1+Antibody/pmc13574648-110-10-13
    Average 96 stars, based on 1 article reviews
    cd80 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology cd80 pe
    Time-dependent differentiation and phenotypic maturation of human monocytes into macrophages. (A) Schematic of the experimental timeline. Upper panel: culture conditions; lower panel: analyses at each time point. Analyses on days 6 and 7 were conducted prior to polarization. (B) Classification of monocyte subsets (CD14/CD16) and macrophages phenotypes (CD68/CD86/CD163). (C) Flow cytometric analysis of monocyte subsets at days 0, 4, 6, and 7 without polarization or neutrophils. Dot plots show CD14/CD16, CD14 + CD86/CD163, CD86/CD163, and CD14/CD68. (D) Representative immunofluorescence images on days 4 and 7 (pre-polarization) under IFN-γ/LPS and IL-4/IL-13 conditions; DAPI (blue), CD68 (green), <t>CD80</t> or CD206 (red). Scale bars, 100 µm. (E) Quantification of CD68 + CD86 + and CD68 + CD163 + macrophages under IFN-γ/LPS and IL-4/IL-13 conditions on day 7 (pre-polarization). n = 5 independent donors.
    Cd80 Pe, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd80/PE+Anti-Mouse+CD80+Antibody/10__1016_slash_j__cej__2026__182168-49-20-26
    Average 94 stars, based on 1 article reviews
    cd80 pe - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework

    Journal: Molecular Biomedicine

    Article Title: EZH2 coordinates inflammatory and pain-associated pathways across joint compartments in osteoarthritis

    doi: 10.1186/s43556-026-00643-w

    Figure Lengend Snippet: Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework

    Article Snippet: The following antibodies were used for immune cell characterization: CD11b (REA592 VioBlue, 130–113–810, Miltenyi Biotec), F4/80 (REA126 PE-Vio770, 130–118–459, Miltenyi Biotec), CD80 (REA983 APC-Vio770, 130–116–463, Miltenyi Biotec), CD86 (REA1190 PE, 130–122–129, Miltenyi Biotec), MHC-II (REA813 FITC, 130–112–386, Miltenyi Biotec), CD38 (REA616 PerCP-Vio700, 130–109–260, Miltenyi Biotec), and iNOS (REA982 APC, 130–116–423, Miltenyi Biotec).

    Techniques: Inhibition, Expressing, ChIP-sequencing, Activation Assay, Derivative Assay

    Time-dependent differentiation and phenotypic maturation of human monocytes into macrophages. (A) Schematic of the experimental timeline. Upper panel: culture conditions; lower panel: analyses at each time point. Analyses on days 6 and 7 were conducted prior to polarization. (B) Classification of monocyte subsets (CD14/CD16) and macrophages phenotypes (CD68/CD86/CD163). (C) Flow cytometric analysis of monocyte subsets at days 0, 4, 6, and 7 without polarization or neutrophils. Dot plots show CD14/CD16, CD14 + CD86/CD163, CD86/CD163, and CD14/CD68. (D) Representative immunofluorescence images on days 4 and 7 (pre-polarization) under IFN-γ/LPS and IL-4/IL-13 conditions; DAPI (blue), CD68 (green), CD80 or CD206 (red). Scale bars, 100 µm. (E) Quantification of CD68 + CD86 + and CD68 + CD163 + macrophages under IFN-γ/LPS and IL-4/IL-13 conditions on day 7 (pre-polarization). n = 5 independent donors.

    Journal: Frontiers in Immunology

    Article Title: Macrophage polarization modulates neutrophil extracellular trap dynamics and reciprocal macrophage responses

    doi: 10.3389/fimmu.2026.1850388

    Figure Lengend Snippet: Time-dependent differentiation and phenotypic maturation of human monocytes into macrophages. (A) Schematic of the experimental timeline. Upper panel: culture conditions; lower panel: analyses at each time point. Analyses on days 6 and 7 were conducted prior to polarization. (B) Classification of monocyte subsets (CD14/CD16) and macrophages phenotypes (CD68/CD86/CD163). (C) Flow cytometric analysis of monocyte subsets at days 0, 4, 6, and 7 without polarization or neutrophils. Dot plots show CD14/CD16, CD14 + CD86/CD163, CD86/CD163, and CD14/CD68. (D) Representative immunofluorescence images on days 4 and 7 (pre-polarization) under IFN-γ/LPS and IL-4/IL-13 conditions; DAPI (blue), CD68 (green), CD80 or CD206 (red). Scale bars, 100 µm. (E) Quantification of CD68 + CD86 + and CD68 + CD163 + macrophages under IFN-γ/LPS and IL-4/IL-13 conditions on day 7 (pre-polarization). n = 5 independent donors.

    Article Snippet: For polarization: CD68 (clone D4B9C, Cell Signaling Technology, 26042SF, 1:200), CD80 (clone 1E2F10, Proteintech, 66406-1-Ig, 1:50), CD206 (clone 2A6A10, Proteintech, 60143-1-Ig, 1:200), For NETs: Myeloperoxidase (MPO; rabbit polyclonal, Abcam, ab9535, 1:150), double-stranded DNA (dsDNA; clone 35I9 DNA, Abcam, ab27156, 1:500), neutrophil elastase (NE; clone NP57, Abcam, ab254178, 1:100), and citrullinated histone H3 (H3Cit; rabbit polyclonal, Abcam, ab5103, 1:100).

    Techniques: Analysis, Immunofluorescence, Co-Culture, Flow Cytometry

    Neutrophil-dependent modulation of macrophage polarization states. (A) Schematic of macrophage polarization states and surface marker profiles. M2 subsets (M2a–d) are defined by differential expression of CD163, CD206, and CD86. (B) Representative immunofluorescence images under IFN-γ/LPS and IL-4/IL-13 conditions after 24 h neutrophil co-culture; DAPI (blue), CD68 (green), CD80 (red). Scale bars, 100 µm. (C) Quantification of macrophage subsets (CD86 – CD163 + [M2-like], CD86 + CD163 + [intermediate], CD86 + CD163 – [M1-like]) following co-culture with neutrophils under concurrently polarized and pre-polarized conditions. (D) Representative flow cytometry histograms of CD86 and CD163 mean fluorescence intensity (MFI) in CD14 + CD16 + and CD14 + CD16 – macrophage subsets. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (Kruskal–Wallis test followed by Dunn’s multiple comparisons test). n = 5 independent donors.

    Journal: Frontiers in Immunology

    Article Title: Macrophage polarization modulates neutrophil extracellular trap dynamics and reciprocal macrophage responses

    doi: 10.3389/fimmu.2026.1850388

    Figure Lengend Snippet: Neutrophil-dependent modulation of macrophage polarization states. (A) Schematic of macrophage polarization states and surface marker profiles. M2 subsets (M2a–d) are defined by differential expression of CD163, CD206, and CD86. (B) Representative immunofluorescence images under IFN-γ/LPS and IL-4/IL-13 conditions after 24 h neutrophil co-culture; DAPI (blue), CD68 (green), CD80 (red). Scale bars, 100 µm. (C) Quantification of macrophage subsets (CD86 – CD163 + [M2-like], CD86 + CD163 + [intermediate], CD86 + CD163 – [M1-like]) following co-culture with neutrophils under concurrently polarized and pre-polarized conditions. (D) Representative flow cytometry histograms of CD86 and CD163 mean fluorescence intensity (MFI) in CD14 + CD16 + and CD14 + CD16 – macrophage subsets. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (Kruskal–Wallis test followed by Dunn’s multiple comparisons test). n = 5 independent donors.

    Article Snippet: For polarization: CD68 (clone D4B9C, Cell Signaling Technology, 26042SF, 1:200), CD80 (clone 1E2F10, Proteintech, 66406-1-Ig, 1:50), CD206 (clone 2A6A10, Proteintech, 60143-1-Ig, 1:200), For NETs: Myeloperoxidase (MPO; rabbit polyclonal, Abcam, ab9535, 1:150), double-stranded DNA (dsDNA; clone 35I9 DNA, Abcam, ab27156, 1:500), neutrophil elastase (NE; clone NP57, Abcam, ab254178, 1:100), and citrullinated histone H3 (H3Cit; rabbit polyclonal, Abcam, ab5103, 1:100).

    Techniques: Marker, Quantitative Proteomics, Immunofluorescence, Co-culture Assay, Flow Cytometry, Fluorescence